Brief: Achilles Therapeutics Details Phase I/Iia Clinical Trial Design Of Chiron In Patients With Advanced Non-Small Cell Lung Cancer At The 2021 American Society Of Clinical Oncology (Asco) Annual Meeting
04/06/2021 15:37
June 4 (Reuters) - Achilles Therapeutics PLC 698y.F :
* ACHILLES THERAPEUTICS DETAILS PHASE I/IIA CLINICAL TRIAL
DESIGN
OF CHIRON IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
AT THE 2021 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL
MEETING
Source text for Eikon: ID:nGNX4PTgWT
Further company coverage: 698y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achilles Therapeutics
See all newsBrief: Achilles Therapeutics Announces Sale Of Technology Assets To Astrazeneca
Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement